Kischel Philippe, Girault Alban, Rodat-Despoix Lise, Chamlali Mohamed, Radoslavova Silviya, Abou Daya Hiba, Lefebvre Thibaut, Foulon Arthur, Rybarczyk Pierre, Hague Frédéric, Dhennin-Duthille Isabelle, Gautier Mathieu, Ouadid-Ahidouch Halima
Laboratoire de Physiologie Cellulaire et Moléculaire (EA 4667), Université de Picardie Jules Verne, UFR des Sciences, 33 Rue St Leu, 80039 Amiens, France.
Service de Gynécologie Obstétrique, CHU Amiens Picardie, 80000 Amiens, France.
Cancers (Basel). 2019 Mar 16;11(3):376. doi: 10.3390/cancers11030376.
In the battle against cancer cells, therapeutic modalities are drastically limited by intrinsic or acquired drug resistance. Resistance to therapy is not only common, but expected: if systemic agents used for cancer treatment are usually active at the beginning of therapy (i.e., 90% of primary breast cancers and 50% of metastases), about 30% of patients with early-stage breast cancer will have recurrent disease. Altered expression of ion channels is now considered as one of the hallmarks of cancer, and several ion channels have been linked to cancer cell resistance. While ion channels have been associated with cell death, apoptosis and even chemoresistance since the late 80s, the molecular mechanisms linking ion channel expression and/or function with chemotherapy have mostly emerged in the last ten years. In this review, we will highlight the relationships between ion channels and resistance to chemotherapy, with a special emphasis on the underlying molecular mechanisms.
在对抗癌细胞的战斗中,治疗方式受到内在或获得性耐药性的极大限制。对治疗的耐药性不仅常见,而且是可预期的:如果用于癌症治疗的全身药物通常在治疗开始时有效(即90%的原发性乳腺癌和50%的转移癌),那么约30%的早期乳腺癌患者会出现疾病复发。离子通道表达的改变现在被认为是癌症的标志之一,并且几种离子通道已与癌细胞耐药性相关联。自20世纪80年代末以来,离子通道一直与细胞死亡、凋亡甚至化疗耐药性相关,但将离子通道表达和/或功能与化疗联系起来的分子机制大多是在过去十年中才出现的。在这篇综述中,我们将重点介绍离子通道与化疗耐药性之间的关系,特别强调其潜在的分子机制。